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Abstract
Fatty liver has been associated with unfavourable metabolic changes in circulation. To provide insights in fatty liver-related
metabolic deviations, we compared metabolic association profile of fatty liver versus metabolic association profiles of geno-
types increasing the risk of non-alcoholic fatty liver disease (NAFLD). The cross-sectional associations of ultrasound-
ascertained fatty liver with 123 metabolic measures were determined in 1810 (Nfatty liver ¼ 338) individuals aged 34–49 years
from The Cardiovascular Risk in Young Finns Study. The association profiles of NAFLD-risk alleles in PNPLA3, TM6SF2, GCKR,
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and LYPLAL1 with the corresponding metabolic measures were obtained from a publicly available metabolomics GWAS in-
cluding up to 24 925 Europeans. The risk alleles showed different metabolic effects: PNPLA3 rs738409-G, the strongest genetic
NAFLD risk factor, did not associate with metabolic changes. Metabolic effects of GCKR rs1260326-T were comparable in many
respects to the fatty liver associations. Metabolic effects of LYPLAL1 rs12137855-C were similar, but statistically less robust, to
the effects of GCKR rs1260326-T. TM6SF2 rs58542926-T displayed opposite metabolic effects when compared with the fatty
liver associations. The metabolic effects of the risk alleles highlight heterogeneity of the molecular pathways leading to fatty
liver and suggest that the fatty liver-related changes in the circulating lipids and metabolites may vary depending on the un-
derlying pathophysiological mechanism. Despite the robust cross-sectional associations on population level, the present
results showing neutral or cardioprotective metabolic effects for some of the NAFLD risk alleles advocate that hepatic lipid
accumulation by itself may not increase the level of circulating lipids or other metabolites.
Introduction
Non-alcoholic fatty liver disease (NAFLD) covers a range of liver
disorders originating from excessive lipid, mainly triglyceride,
accumulation in the liver (1). Fatty liver has been proposed to
result in dyslipidemia due to increased secretion of very low-
density lipoproteins (VLDL) and impaired clearance of interme-
diate and low-density lipoproteins (IDL, LDL) from circulation
(2,3). Studies using detailed metabolic profiling have shown that
fatty liver associates with multiple metabolic aberrations in cir-
culation (4–6). In a study by Kaikkonen et al., fatty liver associ-
ated most prominently with triglycerides in the largest VLDL
particle subfractions as well as with VLDL particle concentra-
tion, but robust associations were also seen with many non-
lipid traits, such as amino acids leucine and isoleucine (4).
Animal models and human studies have shown that liver fat
content correlates with levels of blood lipids and glucose (7–9).
However, fatty liver does not always seem to relate to dyslipide-
mia or changes in glycemic traits (10,11) and thus its effect on
metabolic changes in circulation has remained unclear.
Genetic factors contribute to the pathogenesis of fatty liver.
Four DNA sequence variants, Patatin-like phospholipase do-
main containing 3 (PNPLA3) rs738409-G, Glucokinase regulator
(GCKR) rs780094-T, Neurocan (NCAN) rs2228603-T and Lyso-
phospholipase-like 1 (LYPLAL1) rs12137855-C, were associated
with computed tomography defined steatosis and biopsy-
proven NAFLD involving lobular inflammation and fibrosis
in a large-scale genome-wide association study (GWAS) (12).
Other studies have shown that GCKR rs1260326-T and Trans-
membrane 6 superfamily member 2 (TM6SF2) rs58542926-T are
the functional variants at the GCKR and NCAN loci, respectively
(13–15). PNPLA3 rs738409-G is the strongest genetic risk factor
for NAFLD (16) having an odds ratio of 3.24 for histologic NAFLD
(12). GCKR rs1260326-T and TM6SF2 rs58542926-T are also recog-
nized as important determinants of inter-individual variation in
liver fat (13,17,18). Among these variants, the function of
LYPLAL1 rs12137855-C is the least known.
In the present study, we perform metabolic profiling of
ultrasound-ascertained fatty liver in young and middle-aged
adults. To add insights into molecular mechanisms of fatty
liver-related metabolic aberrations, we compare how the obser-
vational fatty liver associations match with metabolic associa-
tion profiles of the aforementioned NAFLD risk alleles. We
utilize publicly available summary statistics from a metabolo-
mics GWAS to assess the detailed metabolic effects of the risk
variants (19). Understanding the relation between fatty liver
and changes in circulating lipids and metabolites is helpful in
acquiring more opportunities for treatment and prevention of
this complex condition and related cardiometabolic complica-
tions. Cardiovascular disease is the leading cause of death in
patients with fatty liver (20) emphasizing the need of effective
management of cardiovascular health in these individuals.
Results
Fatty liver and circulating metabolites
Characteristics of the YFS study population are shown in Table 1.
Fatty liver showed association with 84 metabolic measures
(P< 0.0004) when adjusted with age, sex and 10 genetic principal
components (Fig. 1, panel 1; Supplementary Material, Figs S2 and
S3; Table S2). Lipoprotein subclass concentrations showed a trend
where the largest VLDL particles displayed the most pronounced
associations that got weaker while the particle size decreased,
and again stronger for medium and small LDL particles (Fig. 1,
panel 1). Concentration of very large and large HDL particles
showed negative association with fatty liver, while small HDL
particles displayed a strong positive association. Fatty liver asso-
ciated with increased VLDL diameter while the associations with
LDL and HDL particle diameters were negative. Fatty liver showed
positive association with apolipoprotein B concentration. Con-
centrations of serum total triglycerides and triglycerides in all li-
poprotein subclasses except very large HDL were increased in
association with fatty liver. Concentrations of circulating total
fatty acids, PUFA, MUFA, and omega-7, -9, and other saturated
fatty acids, and level of fatty acid saturation were increased in as-
sociation with fatty liver, while its association with fatty acid
length was negative. In addition, fatty liver displayed positive as-
sociation with glucose, lactate, pyruvate and glycerol, as well as
with amino acids alanine, isoleucine, leucine, valine, phenyl-
alanine and tyrosine. Association between fatty liver and amino
acid glutamine was negative.
The analysis further adjusted for alcohol consumption
resulted in practically identical association profile with the
Table 1. Study population: YFS
Fatty liver No fatty
liver
Total
population
N 338 1472 1810
Male (%) 237 (70.1) 630 (42.8) 867 (47.9)
BMI, kg/m2 30.56 5.3 25.564.3 26.46 4.9
Age, years 43.06 4.7 41.665.0 41.96 5.0
Smokers (%) 55 (16.3) 198 (13.5) 253 (14.0)
Alcohol consumption
per daya
2.136 1.8 1.8761.6 1.926 1.6
aOne unit equals to 12 g of alcohol.
Values are mean6SD, or absolute N count and corresponding percentage. YFS,
Young Finns Study.
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Figure 1. Cross-sectional associations of fatty liver with lipoprotein particle subfraction concentrations, lipoprotein particle diameter, apolipoproteins, triglycerides,
fatty acids, fatty acid saturation, beta-oxidation, glycolysis, amino acid-related metabolites and inflammation marker GlycA, and the corresponding associations with
four NAFLD risk alleles. Cross-sectional associations were determined in 1, 810 adults aged 34–49 years of whom 338 were diagnosed with ultrasound-based fatty liver.
The metabolic phenotypes were adjusted for age, sex, and 10 first genetic principal components prior to analysis. Genetic effects of the NAFLD risk alleles GCKR
rs1260326-T, LYPLAL1 rs12137855-C, PNPLA3 rs738409-G and TM6SF2 rs58542926-T were acquired from a metabolomics GWAS including up to 24 925 Europeans (19).
Genetic effect estimates were scaled with respect to the NAFLD risk associated with the corresponding locus (12). VLDL, very low-density lipoprotein; IDL, intermediate
density lipoprotein; HDL, high density lipoprotein; PUFA, polyunsaturated fatty acids; MUFA, monounsaturated fatty acids; GlycA, glycoprotein acetylation.
2216 | Human Molecular Genetics, 2018, Vol. 27, No. 12
Downloaded from https://academic.oup.com/hmg/article-abstract/27/12/2214/4966855
by University of Bristol Library user
on 06 August 2018
primary analysis (Supplementary Material, Fig. S2). Adjustment
for BMI attenuated the effect estimates, as expected, but the
overall association pattern was similar to the primary analysis
(Supplementary Material, Fig. S2).
NAFLD risk alleles in GCKR and LYPLAL1 tend to
increase concentrations of circulating lipids
The studied NAFLD risk increasing alleles showed different asso-
ciation profiles on metabolic measures. The association profile of
GCKR rs1260326-T was similar to the one of fatty liver especially
in terms of circulating lipids and lipoproteins (Fig. 1, panel 2;
Supplementary Material, Fig. S3; Table S3). However, some mis-
matches were observed. Glucose concentration showed a tenu-
ous decrease in association with GCKR rs1260326-T while it was
increased in association with fatty liver. Concentrations of amino
acids phenylalanine and tyrosine showed no robust associations
with GCKR rs1260326-T but were increased in association with
fatty liver. Lipoprotein association profiles of the GCKR rs1260326-
T and fatty liver differed in terms of very large and large HDL par-
ticle subfraction concentration and lipid composition: the particle
concentration of the two HDL subfractions together with all lipids
except triglycerides in these subfractions showed only negligible
reduction in association with GCKR rs1260326-T but were highly
decreased in association with fatty liver (Supplementary
Material, Fig. S3). Concentration of apolipoprotein A-I was in-
creased in the GCKR risk allele carriers, while it showed a small
reduction in association with fatty liver. Some differences were
also observed in concentrations of omega-3 fatty acids, docosa-
hexaenoic acid, omega-6 fatty acids and linoleic acid. The results
of GCKR rs780094-T, a variant originally identified as a NAFLD risk
allele in the GCKR locus (12) being in linkage disequilibrium with
the functional GCKR rs1260326-T (13) matched well with the
results of GCKR rs1260326-T (Supplementary Material, Figs S1 and
S3; Table S3).
The association profile of LYPLAL rs12137855-C was similar
to the metabolic effects of GCKR rs1260326-T in terms of highly
correlated point estimates of the two risk alleles
(Supplementary Material, Fig. S4), but the effects of LYPLAL
rs12137855-C were statistically less robust and the effect magni-
tudes were weaker than for the GCKR variant (Fig. 1, panel 3;
Supplementary Material, Fig. S3; Table S3). The high correlation
of the metabolic effects suggests that LYPLAL1 may function on
a related biological pathway with GCKR.
PNPLA3 rs738409-G does not show association with
circulating metabolic traits
PNPLA3 rs738409-G, the strongest genetic contributor to the he-
patic fat content (16), displayed metabolic association profile
close to null (Fig. 1, panel 4; Supplementary Material, Fig. S3;
Table S3). When compared with the fatty liver effects, the
NAFLD risk scaled metabolic effects of PNPLA3 rs738409-G were
much closer to zero, and the confidence intervals for effect esti-
mates of cross-sectional fatty liver and PNPLA3 rs738409-G were
clearly separated.
TM6SF2 rs58542926-T associates with lower-risk lipo-
protein lipid profile and lower glycoprotein acetylation
TM6SF2 rs58542926-T displayed strong association profile in
particular on the lipoprotein lipid traits (Fig. 1, panel 5;
Supplementary Material, Fig. S3; Table S3). However, the
associations were negative indicating lower concentrations of
the lipids and metabolites in relation to higher NAFLD risk. The
TM6SF2 variant associated with lower concentrations of all the
VLDL, IDL and LDL particle subclasses and all the lipid species
in these subclasses. In addition, the variant associated inversely
with serum total triglycerides and triglycerides in all the lipo-
protein subclasses including the HDL subclasses. The variant
associated with smaller VLDL particle diameter, while it did not
show an effect on LDL nor HDL particle size. The TM6SF2
rs58542926-T associated with lower concentration of the apoli-
poprotein B but did not influence concentration of apolipopro-
tein A-I. It associated inversely also with all the fatty acid
concentrations, while the qualitative measures such as fatty
acid length or saturation measures were not influenced by this
variant. In addition, the T allele associated with lower levels of
glycerol and glycoprotein acetylation, a marker for inflamma-
tion (21). The results for NCAN rs2228603-T in the same NAFLD
risk locus can be found in the supplement (Supplementary
Material, Figs S1 and S3; Table S3).
Resemblance of the metabolic effects
The correspondence between the metabolic effects of the risk
alleles and observational fatty liver was the highest between the
GCKR rs1260326-T and fatty liver (R2¼ 0.77; Fig. 2C). The remain-
ing coefficients of determination were R2¼ 0.67 for LYPLAL1
rs12137855-C versus fatty liver (Fig. 2D), R2¼ 0.45 for TM6SF2
rs58542926-T versus fatty liver (Fig. 2B) and R2¼ 0.30 for PNPLA3
rs738409 G versus fatty liver (Fig. 2A).
Pairwise comparisons of the risk allele association profiles in-
dicated that the effects of GCKR rs1260326-T and LYPLAL1
rs12137855-C on circulating metabolites were highly similar
(R2¼ 0.71; Supplementary Material, Fig. S4). The overall pattern
of metabolic effects of TM6SF2 rs58542926-T correlated inversely
with effects of both GCKR rs1260326-T and LYPLAL1 rs12137855-C
(R2¼ 0.66, and R2¼ 0.50, respectively; Supplementary Material,
Fig. S4). The remaining correlations were weaker (0.19R2 0.24;
Supplementary Material, Fig. S4).
To control for intercorrelation of the lipoprotein lipid traits,
we further examined the correlations of metabolic effects using
a subset of metabolic measures that represented independent
clusters (k¼ 29) identified in the YFS metabolomics data
(Supplementary Material, Fig. S5). The magnitudes of coeffi-
cients of determination were somewhat smaller than using the
full data, as expected, but supported the findings of the primary
analysis (Supplementary Material, Fig. S6).
Discussion
We determined fatty liver-related metabolic changes in 1810
young and middle-aged Finns using 123 circulating metabolic
measures assessed by NMR-based platform. We further com-
pared the cross-sectional observations with metabolic signa-
tures of known NAFLD risk alleles obtained from a publicly
available metabolomics GWAS including up to 24 925 individu-
als (19). The studied NAFLD risk alleles resulted in divergent
metabolic association profiles. Despite PNPLA3 rs738409-G being
the strongest genetic risk factor for NAFLD (16), it showed a null
effect on circulating lipids and metabolites. Association profile
of GCKR rs1260326-T was similar to the cross-sectional fatty
liver associations, whereas TM6SF2 rs58542926-T provided evi-
dence to the opposite direction. The present results provide
metabolomic evidence supportive to the recent findings about
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worsened metabolic features seen in association with obesity-
linked NAFLD, but not with NAFLD arising due to risk alleles in
PNPLA3 and TM6SF2 (17,22,23). In turn, the more risk-prone met-
abolic association profile of the NAFLD risk allele in GCKR
underlines the importance of proper regulation of glucose me-
tabolism in both liver and cardiovascular health.
The metabolic association profiles reflect the biological func-
tions of the risk alleles and suggest that the distinct molecular
pathways giving rise to fatty liver may have divergent effects on
circulating metabolome. The three pathways studied here are
summarized in Figure 3. Pathway I, excessive hepatic glucose levels
and amplified lipogenesis: GCKR rs1260326-T reduces GCKR ability
to inhibit glucokinase resulting in enhanced hepatic glucose up-
take, reduced fatty acid oxidation and increased lipogenesis
(24). Hepatic fatty acids can be converted to triglycerides to be
stored in hepatic lipid droplets or secreted in VLDL particles
(25), where they can contribute respectively to development of
steatosis or to levels of circulating lipids. Congruent with these
observations, GCKR rs1260326-T increases risk of fatty liver
(12,13) and raises concentrations of all the apolipoprotein B con-
taining lipoprotein particles and triglycerides in these particles,
while circulating glucose level is marginally reduced (Fig. 1,
panel 2). GCKR rs1260326-T associates also with elevated levels
of glycolysis-related metabolites, circulating fatty acids and in-
creased fatty acid saturation (Fig. 1, panel 2) compatible with
the enhanced glycolytic and lipogenic activities promoted by
this variant (24,26,27). The amino acid association profile of
GCKR rs1260326-T differs from the one of fatty liver in terms of
concentrations of phenylalanine and tyrosine, both of which
were increased in association with cross-sectional fatty liver
but unaltered by the GCKR variant (Fig. 1, panel 1).
Phenylalanine levels have been associated with cardiovascular
disease risk (28) while tyrosine is linked with incidence of diabe-
tes (29); the differences in the effects on the two biomarkers and
on the two largest HDL subclasses and their lipids may be indic-
ative to molecular pathways explaining why GCKR rs1260326-T
rises concentrations of circulating lipids but does not seem to
increase risk of cardiometabolic complications (30,31) as fatty
liver does. LYPLAL1 rs12137855-C variant has a metabolically
highly similar but statistically less robust effect than the GCKR
rs1260326-T, as seen in highly correlated effect estimates of the
two (Supplementary Material, Fig. S4). This finding advocates
that LYPLAL1 may contribute to circulating and hepatic triglyc-
eride levels by regulating hepatic glucose metabolism as does
GCKR. This is supported by the discovery by Ahn et al. who
showed that LYPLAL1 inhibition leads to increase in glucose pro-
duction in human, rat and mouse hepatocytes (32).
Pathway II, reduced VLDL secretion: TM6SF2 contributes to
VLDL secretion from the liver (33). In mice, knockdown of
Tm6sf2 triplicates hepatic triglyceride content while blood lipids
Figure 2. The overall match between the metabolic effects of the NAFLD risk alleles and fatty liver. The black dashed line shows the linear fit between metabolic
changes associated with fatty liver and PNPLA3 rs738409-G (A), TM6SF2 rs58542926-T (B), GCKR rs1260326-T (C) and LYPLAL1 rs12137855-C (D). The grey area indicates
the 95% confidence interval for the line. R2 is a measure of goodness of fit.
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are decreased (14). Conversely, overexpression of human
TM6SF2 in mice increases serum lipids levels (15). The NAFLD
risk allele TM6SF2 rs58542926-T is a loss-of-function variant
resulting in a misfolded protein undergoing accelerated degra-
dation (14). The mechanism leading to impaired lipidation, sub-
sequent degradation and thus reduced secretion of VLDL
particles seem to be due to deficiency in polyunsaturated phos-
phatidylcholines in TM6SF2 rs58542926-T carriers (34). This al-
lele associates with reduced concentrations of multiple lipid
species in circulation while it has no influence on qualitative
measures of circulating lipids, such as fatty acid saturation
(Fig. 1, panel 5). The inverse associations between TM6SF2
rs58542926-T and all the circulating VLDL particle subclass con-
centrations, lipid species within the lipoprotein subclasses, as
well as apolipoprotein B concentration are supportive for
TM6SF2 rs58542926-T disturbing both lipidation and secretion of
VLDL particles in humans. This differs from the observation of a
study with Tm6sf2/ mice, which provided evidence that
mouse Tm6sf2 is required for lipidation of VLDL, but lack of it
does not influence VLDL secretion (35). Our results are compati-
ble with lipidomic effects of TM6SF2 rs58542926-T (36) and stud-
ies that associated this variant with a favourable plasma lipid
profile and cardioprotective effect at the expense of increased
risk for progressive NAFLD (17,37). Interestingly, TM6SF2
rs58542926-T associates with lower level of glycoprotein acety-
lation, a marker for inflammation (Fig. 1, panel 5), indicating
that its cardioprotective effect is not limited only to lipoprotein
and lipid metabolism. However, the same allele has been asso-
ciated with increased risk of type 2 diabetes (38) underlining its
complex effect on systemic metabolism.
Pathway III, impairment of triglyceride mobilization from hepatic
lipid storage: PNPLA3 is located in the endoplasmic reticulum
and lipid droplet membranes in human hepatocytes and shows
both acyltransferase and hydrolase activities on glycerolipids
(39–41). Despite the intensive research on the topic, the exact
mechanism of how the common variant rs738409-G promotes
development of liver disease is not clear. Several studies advo-
cate that the variant inhibits triglyceride hydrolysis (39,41,42)
possibly arising from accumulation of inactive PNPLA3 on lipid
droplets disturbing mobilization of lipids (43,44). Some studies
have shown that this risk allele does not influence common
blood lipid traits, triglyceride profile, nor glucose homeostasis
(10,11,22), while some studies have associated rs738409-G with
lower lipid levels and protection from cardiovascular disease
(45,46). The present results extend the findings of previous stud-
ies from common blood lipid traits to detailed fatty acid, amino
acid and lipoprotein subfraction measures, and confirms the
perception that rs738409-G has only minimal, if any, contribu-
tion to the metabolic traits in circulation (Fig. 1, panel 4). Our
results are compatible with a mouse model where Pnpla3148M/M
knock-in mice show no differences in levels of circulating lipids
and glucose in comparison with wild-type mice regardless of
the increase in liver triglycerides (43). These observations advo-
cate that hepatic lipid accumulation can be neutral for circula-
tory changes and that the strong cross-sectional associations
are largely due to lifestyle-related aspects such as dietary fac-
tors, excess energy intake or sedentary lifestyle. Dietary lipids
and sugars and adipose tissue-derived fatty acids supply the
fatty acid pool upstream from the lipid storage and secretion
pathways (25), and consequently overnutrition could contribute
to both fatty liver development as well as altered metabolic pro-
file. The importance of nutritional factors is highlighted also
when determining genetic risk for NAFLD, as adiposity has been
shown to amplify the effect of the NAFLD risk alleles in PNPLA3,
TM6SF2 and GCKR (47).
This study has some limitations. We examine a limited
number of NAFLD risk alleles while there are multiple other ge-
netic pathways contributing to pathogenesis of NAFLD
(16,48,49). However, the risk alleles in PNPLA3, TM6SF2 and
GCKR are important determinants of liver fat content and thus
the current study setting covers some of the fundamental path-
ways involved in NAFLD pathogenesis (13,14). The role of the
LYPLAL1 variant in NAFLD pathogenesis needs additional as-
sessment; however, the current results provide a novel insight
into LYPLAL1 function, which potentially helps in directing the
focus of further studies. Regarding the cross-sectional associa-
tions, ultrasound lacks sensitivity to detect mild steatosis (50),
leading to conservative association magnitudes. Despite the
known deficiencies, ultrasound is a feasible method to be used
for liver screening in a large population study. Also, the study
populations compose of relatively young European individuals,
and the present findings would need to be confirmed in other
demographic groups. A recent study with 300 000 individuals
detected a small effect for the PNPLA3 risk allele (46), and thus it
is likely that with a larger sample size we would also see a small
effect. However, when considering the great NAFLD risk in-
crease associated with this variant (12), the relative effect on
Figure 3. Relation of the studied NAFLD risk alleles to the main pathways in he-
patic triglyceride partitioning. Liver converts carbohydrates to lipids in de novo li-
pogenesis. Newly synthesized fatty acids enter to the hepatic fatty acid pool
which is also supplied by dietary fats and circulating free fatty acids derived
mostly from adipose tissue lipolysis or lipoprotein lipase spillover (1,25). Fatty
acids can be partitioned to oxidative pathway or esterified to triglycerides that
can be stored in hepatic lipid droplets or used for VLDL production to be secreted
from the liver (1,25). The hepatic fatty acid pool is located upstream from the
lipid storage and secretion pathways, and thus abundance in hepatic fatty acids
can contribute to both development of fatty liver and increased production of
VLDL. In line with this, GCKR rs1260326-T that enhances the lipogenic pathway
by providing more substrates for fatty acid biosynthesis (24) increases risk of
fatty liver (12,13) and raises concentrations of all the apoB containing lipopro-
teins and lipids in these particles while circulating glucose level is marginally re-
duced (Fig. 1). LYPLAL1 may be functioning on the same hepatic glucose
metabolism and lipogenesis related pathway, as the metabolic effects of GCKR
rs1260326-T and LYPLAL1 rs12137855-C are highly similar (Supplementary
Material, Fig. S4). On the contrary, TM6SF2 rs58542926-T impairs the secretory
pathway leading to lipid accumulation into the liver (14) and reduction in levels
of circulating lipids and lipoproteins (Fig. 1). PNPLA3 rs738409-G, in turn, enhan-
ces triglyceride accumulation to the storage pool by diminishing triglyceride hy-
drolysis to fatty acids (41,42), but does not directly contribute to VLDL secretion,
and thus conveys no major consequences to circulation (Fig. 1).
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the circulating metabolic measures is minute. The strength of
the metabolomics panel used is in detailed lipoprotein metabo-
lism, while alternative techniques for metabolic profiling, such
as a more detailed lipidomics platform (51), may reveal other
biomarker changes associated with NAFLD induced by the stud-
ied risk alleles. The metabolic traits captured with the current
panel include multiple known biomarkers of cardiometabolic
diseases (52,53). Importantly, these biomarkers show strong
associations with fatty liver, and the studied risk alleles show
divergent effects on the corresponding measures underlining
the heterogeneous nature of fatty liver.
The present study illustrates how open-access omics data
can be utilized in evaluation of molecular mechanisms complex
traits, such as NAFLD. The divergence in the direction of the
risk allele association profiles advocates that different molecu-
lar pathways leading to NAFLD may have alternate effects on
circulating lipids and other metabolites. We highlight the mini-
mal metabolic effect of the strongest genetic determinant of
NAFLD, PNPLA3 rs738409-G, and the cardioprotective effect of
the TM6SF2 rs58542926-T on circulating lipids. Our findings sug-
gest that, despite the strong population level associations, he-
patic lipid accumulation by itself does not necessarily increase
the risk of hyperlipidemia associated with cardiometabolic
complications.
Materials and Methods
Study population
The Cardiovascular risk in Young Finns Study (YFS) is a
population-based follow-up study started in 1980. In 2011, 2046
individuals aged 34–49 years participated to ultrasound imaging
of the liver (Acuson Sequoia 512, Acuson, Mountain View, CA,
USA). In total, fatty liver was diagnosed in 18.6% (N¼ 372) of the
participants. The population and ultrasound imaging of the
liver are described in more detail by Kaikkonen et al. (4) and
Suomela et al. (54). After exclusion of pregnant women and indi-
viduals using lipid lowering medication or oral contraceptives,
the total number of individuals included in the analysis was
1810 (Nfatty liver ¼ 338). The study was approved by the local
Ethics Committee and written informed consent was obtained
from all the participants.
Metabolic effects of NAFLD risk alleles
Effect estimates of PNPLA3 rs738409-G, GCKR rs1260326-T, GCKR
rs780094-T, TM6SF2 rs58542926-T, NCAN rs2228603-T and
LYPLAL1 rs12137855-C on the metabolic measures were ac-
quired from a GWAS performed using 14 European cohorts in
up to 24 925 individuals (19). The mean age and BMI of the par-
ticipants per cohort ranged from 23.9 to 61.3 years and from 23.1
to 28.2 kg/m2 with the whole sample means being 46.3 years
and 26.0 kg/m2. The genotyping methods are described in the
original publication (19).
Risk allele frequencies and odds ratios to NAFLD for the
studied loci are described in Table 2. To facilitate comparison of
the risk allele associated metabolic changes relative to NAFLD
risk increase, the risk allele effects and related 95% confidence
intervals were scaled with respect to the log(odds ratio) on his-
tologic NAFLD associated with the corresponding locus in a
large-scale GWAS (12). Scaling the metabolic associations with
respect to a common factor allows evaluation of the effect simi-
larities regardless of the magnitude of the absolute effect, which
can be helpful when the study interest is on the metabolic path-
ways involved rather than in the absolute effects. The same
principle has been applied for example in a study comparing
metabolic effects of statin treatment versus genetic inhibition
of HMGCR, where the large difference in the absolute effects of
statins and HMGCR rs12916 genotype was overcome by scaling
the metabolic effects to the magnitude on LDL-C lowering (55).
P-values for the genetic effects were derived directly from the
metabolomics GWAS (19).
Metabolic profiling
Metabolic profiling of all samples included were assessed using a
nuclear magnetic resonance (NMR) metabolomics platform de-
scribed in (19) and reviewed in (52,53). To determine the cross-
sectional metabolic associations of fatty liver, we utilized 123
metabolic measures representing a broad molecular signature of
systemic metabolism (Supplementary Material, Table S1).
Statistical analyses
All analyses were done using R version 3.2.2. Due to the correla-
tion of the metabolic measures, the number of independent
tests performed is lower than the total number of 123 metabolic
Table 2. Description of NAFLD risk increasing genotypes extracted from the open access data
NAFLD GWAS by Speliotes et al. (12) Metabolomics GWAS
by Kettunen et al. (19)
Gene dbSNP
reference
EA Locus OR for histologic
NAFLD (95% CI)
EAF EAF
PNPLA3 rs738409 G 3.24 (2.83–3.72) 0.23 0.23
NCAN rs2228603 T 1.90 (1.55–2.34) 0.07 0.07
*TM6SF2 rs58542926 T NA 0.06
LYPLAL1 rs12137855 C 1.21 (1.02–1.43) 0.79 0.74
GCKR rs780094 T 1.18 (1.05–1.34) 0.39 0.37
*GCKR rs1260326 T NA 0.36
DNA sequence variants studied in the present study were associated with computed tomography characterized steatosis and biopsy-proven NAFLD involving liver in-
flammation and fibrosis by Speliotes et al. (12). The functional variants explaining the NAFLD associations of NCAN rs2228603 and GCKR rs780094 are denoted sepa-
rately (*). To achieve coherency, the NCAN locus is referred as TM6SF2 throughout the paper.
PNPLA3, Patatin-like phospholipase domain containing 3, NM_025225; NCAN, Neurocan, NM_004386; TM6SF2, Transmembrane 6 superfamily member 2,
NM_001001524; LYPLAL1, Lysophospholipase-like 1, NM_001350628; GCKR, Glucokinase regulator, NM_001486; SNP, single-nucleotide polymorphism; EA, effect allele;
OR, odds ratio; NAFLD, non-alcoholic fatty liver disease; EAF, effect allele frequency; NA, not available.
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traits examined. We considered statistical significance at
< 0.0004 (0.05/22/5), where 22 is the number of principal compo-
nents explaining 95% of the variation in the NMR metabolomics
data (19) and five is the number of analyses conducted.
Cross-sectional associations
Linear regression models were fitted to determine the cross-
sectional associations of fatty liver with each of the metabolic
measures in the YFS population. To enable the comparison of
cross-sectional and genetic effect estimates, the data processing
and analysis model were done correspondingly to Kettunen
et al. (19): the metabolic phenotypes were adjusted for age, sex
and 10 first genetic principal components preceding the analy-
sis, and the resulting residuals were transformed to normal dis-
tribution by inverse rank-based normal transformation. The
adjusted and transformed metabolic phenotypes were used as
outcomes in the equations and fatty liver served as a categorical
variable (fatty liver vs. no fatty liver). Secondary analyses were
conducted with additional adjustment for alcohol consumption
or BMI to evaluate the possible contribution of alcoholic fatty
liver and obesity to the observed metabolic changes. The ge-
netic principal components were calculated using PLINK soft-
ware on linkage disequilibrium pruned markers after removing
variants with more than 5% missing data and poorly genotyped
samples with more than 5% missing data.
Comparisons of the metabolic association profiles
The overall resemblance between the risk alleles and fatty liver
effects on metabolites was determined by a linear fit of each of
the risk allele association profile versus cross-sectional fatty liver
association profile (55). In addition, the linear fit of all the pairs of
the risk allele association profiles were determined to identify
alleles with similar metabolic effects informing about gene prod-
ucts functioning in related biological pathways. This method was
also used to ensure that the metabolic profiles of the NAFLD risk
alleles GCKR rs780094-T and NCAN rs2228603-T correspond to
ones of GCKR rs1260326-T and TM6SF2 rs58542926-T that have
been identified as the functional variants in GCKR and NCAN/
TM6SF2 loci, respectively (13–15).
Due to the correlated nature of the lipoprotein lipid measures,
we completed sensitivity analyses on the correlation tests with a
subset of metabolic measures: we first assessed independent
clusters of the metabolic measures in the YFS population using
hierarchical clustering and gap statistics in factoextra R package,
and then selected one metabolic measure per identified cluster
for re-evaluation of the resemblance of the metabolic effects.
Supplementary Material
Supplementary Material is available at HMG online.
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